Home banner
Divider
A-Z Index

Quick way to the find the information that you need...

More button
Register with FRAME

Although you do not need to register, any information you provide will be confidential and used only by FRAME to improve the website

Register button
Account Login
Forgot password?

ATLA - ISI
The Journal

 

Alternatives to Laboratory Animals - ATLA

Download latest issue button Download back issues button Subscribe to ATLA
Contact Us

Tel icon

Tel: +44 (0)115 9584740


Tel icon

Fax: +44 (0)115 9503570

Make an Enquiry

FRAME welcomes animal-free procedure for testing Botox©

NeedleThe Humane Society of the US has issued the following press release. FRAME is delighted at the outcome of one of its long-standing campaigns.

 

The HSUS and Calvert Investments Applaud Allergan for Developing an Animal-Free Procedure for Testing Botox©

 

The Humane Society of the United States and Calvert Investments applaud Allergan’s announcement that the company has developed  – and received federal approval for – a new procedure that avoids using animals in testing batches of Botox© products. 

 

The industry standard for assessing the potency and stability of Botox-like products has been the LD50 test, which subjects animals to considerable suffering and results in death by asphyxiation.  According to an Allergan press release, the company spent more than 10 years and $65 million conducting research to develop the new test and secured approval from the U.S Food and Drug Administration on Friday. The company expects the new method will reduce its use of animals in Botox© testing by 95 percent within three years.

 

“CEO David Pyott has delivered on his promise that Allergan would invest the money and expertise necessary to develop an animal-free method of testing batches of Botox©,” stated Martin Stephens, Ph.D., vice president for animal research issues for The HSUS. “We now urge Allergan to work with companies that manufacture products with active ingredients similar to that used in Botox©, to see if the new method can be tailored to those products, thereby sparing additional animals.  In the European Union alone, tens of thousands of animals are estimated to be used in this testing per year, and this use has been increasing.”

 

“We commend Allergan on gaining regulatory approval in the United States for its new test and we welcome the FDA’s approval of the alternative method,” stated Ellen Kennedy, senior sustainability analyst for Calvert Investments, which joined the HSUS in co-filing shareholder resolutions with Allergan to ensure the company’s commitment to progress on this issue.  “We urge Allergan to move expeditiously to secure approvals in Botox© markets outside of the United States.”

 

Timeline

1927:   The LD50 test is developed to assess the potency and safety of therapeutic agents that vary from batch to batch.  “LD50” stands for Lethal Dose-50 percent and, in a typical LD50 test, around half the animals will die from the effects of the test agent.  

 

2003:   An exposé by FRAME indicates that the LD50 test, which is otherwise waning, is used to standardise batches of Botox© and similar products, the demand for which has been growing.

 

2004:   The HSUS approaches Allergan about its use of animals in Botox© testing in January of 2004, asking the company to replace the LD50 test with appropriate non-animal systems.  In October of 2004, The HSUS appealed to its members to contact Allergan to urge the company to replace the LD50 with a non-animal alternative. 

 

2007:   Allergan posts a statement on its website about its animal testing, including for Botox©.

 

2008:   The HSUS and Calvert Investments file a shareholder resolution urging greater transparency in Allergan’s efforts to replace the LD50 test.  At the shareholder meeting, the resolution receives nearly double the number of supportive votes to allow the resolution to be refiled in 2009.

 

2009:   A second HSUS/Calvert resolution gains enough votes to comfortably exceed the six percent threshold to allow the resolution to be refiled in 2010.  At the shareholder meeting, Allergan CEO David Pyott affirms the company’s commitment to develop a non-animal replacement for the LD50 test.

 

2010:   The HSUS and Calvert withdraw their third resolution after Allergan revises its website statement on Botox© testing, providing an update on its progress towards developing an alternative test and affirming in writing its commitment to finish the job.

 

*********

Chairman of the FRAME Trustees Professor Michael Balls said: "This is good news. FRAME started this off in 2003, with an article in ATLA, as is recognised in the HSUS press release.
 
"Since then, we have been working in collaboration with the HSUS. They have focused on the US, while we have dealt with the situation in the UK."

The ATLA article can be found by clicking here.

 

Archived July 18, 2011